Related Experiment Videos
EBV specific CTL: a model for immune therapy
C M Rooney1, H E Heslop, M K Brenner
1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. cmrooney@msmail.his.tch.tmc.edu
Vox Sanguinis
|August 15, 1998
Abstract:
We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.